Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 32%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is well positioned for future growth with its pipeline of new products such as the Mobi Tubeless patch pump. This, combined with a transition to a PayGo model and expected growth in the pharmacy channel, is expected to drive revenue growth and potential margin expansion. However, the company will need to continue to innovate and secure favorable contracts in a competitive market in order to maintain its success in the long term.

Bears say

Tandem Diabetes Care is experiencing short-term supply chain challenges in its infusion set segment, negatively impacting both its US and international revenue. Additionally, the company's newest pump, the Mobi, is facing delays in FDA approval and is not included in Tandem's 2026 revenue guidance. The company is also in the early stages of transitioning its US business from the traditional DME channel to pharmacy, and while management expects this shift to result in significant revenue growth in 2027 and 2028, there is uncertainty around the conversion timeline and potential impact on near-term revenues.

TNDM has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 32% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 19 analysts, TNDM has a Buy consensus rating as of Jun 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.